AMN Healthcare Services (AMN)
(Delayed Data from NYSE)
$42.57 USD
-0.06 (-0.14%)
Updated Sep 27, 2024 04:00 PM ET
After-Market: $42.57 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
A Value C Growth A Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$42.57 USD
-0.06 (-0.14%)
Updated Sep 27, 2024 04:00 PM ET
After-Market: $42.57 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
A Value C Growth A Momentum A VGM
Zacks News
Here's Why You Should Retain Edwards Lifesciences (EW) Stock
by Zacks Equity Research
Investors are optimistic about Edwards Lifesciences (EW) on continued strong adoption of the SAPIEN 3 Ultra platform and the PASCAL system.
New Strong Buy Stocks for February 2nd
by Zacks Equity Research
CVX, PSX, UMC, AMN, and GPRO have been added to the Zacks Rank #1 (Strong Buy) List on February 2, 2022.
PerkinElmer (PKI) Q4 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
PerkinElmer's (PKI) fourth-quarter results benefit from solid performance at Discover & Analytics Solutions business.
Catalent (CTLT) Q2 Earnings Top Estimates, FY22 View Up
by Zacks Equity Research
Catalent's (CTLT) robust performance across most of its segments drives its second-quarter fiscal 2022 top line.
Here's Why You Should Retain West Pharmaceutical (WST) Now
by Zacks Equity Research
West Pharmaceutical (WST) continues to gain momentum on the back of strength in the Proprietary Products business. However, forex woes persist.
Premier, Inc. (PINC) Q2 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Premier, Inc. (PINC) delivered earnings and revenue surprises of 10.61% and 8.83%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
McKesson (MCK) Hits 52-Week High: What's Aiding the Stock?
by Zacks Equity Research
Investors are optimistic about McKesson's (MCK) strength in its Biologics business.
Cardinal Health (CAH) to Post Q2 Earnings: What's in Store?
by Zacks Equity Research
Cardinal Health's (CAH) fiscal second-quarter results are likely to reflect solid performance in the Pharmaceutical segment.
Diagnostics Sales to Drive Hologic's (HOLX) Q1 Earnings
by Zacks Equity Research
Strength in the Diagnostics division is likely to have contributed to Hologic's (HOLX) fiscal first-quarter revenues.
New Strong Buy Stocks for January 31st
by Zacks Equity Research
ADM, MSBI, USAK, WHR, and AMN have been added to the Zacks Rank #1 (Strong Buy) List on January 31, 2022.
AMN Healthcare Services (AMN) Gains But Lags Market: What You Should Know
by Zacks Equity Research
In the latest trading session, AMN Healthcare Services (AMN) closed at $99.51, marking a +0.35% move from the previous day.
BD (BDX) Gears Up for Q1 Earnings: What's in the Offing?
by Zacks Equity Research
Continued strength in BD's (BDX) Life Sciences and Interventional segments is expected to have driven up Q1 sales.
Stryker (SYK) Q4 Earnings Miss Estimates, Revenues Beat
by Zacks Equity Research
Despite pandemic-led disruptions, Stryker's (SYK) fourth-quarter earnings reflect strong performance across its segments.
ResMed (RMD) Q2 Earnings in Line, Revenues Miss Estimates
by Zacks Equity Research
ResMed's (RMD) Q2 earnings meet estimates, with robust demand for sleep and respiratory care devices driving the top line.
McKesson (MCK) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
McKesson's (MCK) fiscal third-quarter results are likely to reflect the solid show by the U.S. Pharmaceutical and Specialty Solutions segment.
Hologic (HOLX) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Strength in Diagnostics and Breast Health businesses is likely to have contributed to Hologic's (HOLX) fiscal first-quarter revenues.
Abiomed (ABMD) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Continued strength in Abiomed's (ABMD) Impella product line is expected to have driven up Q3 sales.
AmerisourceBergen (ABC) to Post Q1 Earnings: What's in Store?
by Zacks Equity Research
AmerisourceBergen's (ABC) fiscal first-quarter results are likely to reflect solid performance at the U.S. Healthcare Solutions segment.
CONMED's (CNMD) Q4 Earnings Beat Estimates, Revenues Miss
by Zacks Equity Research
CONMED's (CNMD) fourth-quarter earnings reflect strong segmental performance.
Accuray (ARAY) Q2 Earnings Miss Estimates, Margins Down
by Zacks Equity Research
Accuray (ARAY) registers growth in Products revenues during fiscal Q2, thereby partly driving its overall top line.
NextGen Healthcare (NXGN) Beats on Q3 Earnings, Ups FY22 View
by Zacks Equity Research
NextGen Healthcare's (NXGN) fiscal third-quarter earnings reflect strength in both of its revenue sources.
Align Technology (ALGN) to Post Q4 Earnings: What's in Store?
by Zacks Equity Research
Robust scanner shipments and an increase in Invisalign volumes within the teen segment are expected to have contributed to Align Technology's (ALGN) Q4 performance.
IDEXX (IDXX) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Strong organic recurring revenue growth in the CAG diagnostics business and rise in new instrument placements are likely to have contributed to IDEXX's (IDXX) Q4 revenues.
Best Value Stocks to Buy for January 27th
by Zacks Equity Research
UMC, AMN, and FNB made it to the Zacks Rank #1 (Strong Buy) value stocks list on January 27, 2022
New Strong Buy Stocks for January 27th
by Zacks Equity Research
AMN, UMC, MRTN, FNB, and SLB have been added to the Zacks Rank #1 (Strong Buy) List on January 27, 2022.